Sign in Subscribe
Pediatrics

Novel Insights into Sphingolipid Dysregulation in Childhood-Onset Amyotrophic Lateral Sclerosis

Strategic Insights

— 1 min read

Researchers at the Uniformed Services University of the Health Sciences have made a groundbreaking discovery in the field of neurodegenerative diseases, shedding light on the role of sphingolipid dysregulation in childhood-onset amyotrophic lateral sclerosis (ALS). The study, published in the Journal of Neuromuscular Diseases, reveals a novel variant linked to this rare and severe condition, providing new avenues for targeted therapeutic interventions.

Key Takeaways:

  • The research identified a novel heterozygous de-novo variant (c.197T G, p.T66R) in the SPTLC2 gene associated with childhood-onset ALS, a severe neurodegenerative disorder.
  • The study recruited two Chinese patients, a 6-year-old male and a 7-year-old female, both carrying SPTLC2 mutations, who exhibited distinct sphingolipid profiles and elevated levels of specific sphingolipids compared to controls.
  • The researchers demonstrated that the p.T66R mutation reduces the inhibitory regulation of SPT by ORMDL proteins, leading to unrestrained SPT activity and excess sphingolipid production in mutant cell lines.
  • The findings highlight the importance of sphingolipid metabolism in ALS and suggest potential avenues for targeted therapeutic interventions, including modulating sphingolipid levels and correcting genetic defects.

Statistics:

  • The study reported two childhood-onset ALS cases with distinct SPTLC2 mutations, providing new insights into sphingolipid dysregulation and its role in ALS pathogenesis.
  • The researchers identified a novel variant linked to childhood-onset ALS, the p.T66R mutation, which was predicted to alter protein interactions within the SPT complex.
  • The study found that both patients exhibited elevated levels of specific sphingolipids compared to controls, with distinct profiles between the -ALS and -hereditary sensory and autonomic neuropathy type 1 (HSAN1) cases.
  • The research concluded that further studies are needed to explore treatment options aimed at modulating sphingolipid levels and correcting genetic defects, as well as investigating potential biomarkers for early diagnosis.

Sources:

  • "Characterization of novel and recurrent SPTLC2 variants in childhood-onset amyotrophic lateral sclerosis: Insights into sphingolipid dysregulation". Journal of Neuromuscular Diseases, 2025:22143602251370586.
  • Ios Press, Nieuwe Hemweg 6B, 1013 Bg Amsterdam, Netherlands (Publisher contact information for the Journal of Neuromuscular Diseases)
  • Uniformed Services University of the Health Sciences, Bethesda, MD, United States (Research institution)
  • Kenneth Gable, Dept. of Biochemistry and Molecular Biology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States (Corresponding author)
  • Xiaona Fu, Sita D. Gupta, KaiLi Zhang, Bingbing Jia, Wenjun Wang, Xinying Yang, Lu Wang, Lin Ge, Carsten G. Bonnemann, Teresa M. Dunn, and Hui Xiong (Additional authors)

Read more